Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2016-10-20

FDA Approved: ANTHIM — Supplemental Application (Elusys Therapeutics, Inc.)

View source ↗

Summary

FDA approved a supplemental application for ANTHIM (obiltoxaximab) from Elusys Therapeutics, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ANTHIM (obiltoxaximab)

Snippet

SUPPL AP for ANTHIM (OBILTOXAXIMAB)